Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib [2]

Leukemia

Volumn 18, Issue 6, 2004, Pages 1140-1142

  Guilbert Douet, N ^a,b   Morel, F ^a,b   Le Bris, M J ^a   Berthou, C ^a,b   Morice, P ^c   Bourquard, P ^c   De Braekeleer, Marc D ^a,b  

^a CHU MORVAN   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^c Centre Hospitalier La Beauchee   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LEUKEMIA; ADULT; AGED; APOPTOSIS; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; MALE; MONOSOMY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; ONCOGENE C KIT; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRISOMY; CELL CLONE; GENETICS; MYELOID LEUKEMIA;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CLONE CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; PIPERAZINES; PYRIMIDINES;

EID: 2942657660     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403361     Document Type: Letter

References (13)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
2. Capdeville R, Buchdunger E, Zimmerman J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. for the International STI571 CML Study Group Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
4. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461-463.
5. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-487.
6. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003; 17: 465-467.
7. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88: 260-267.
8. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100: 435-441.
9. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390-1393.
10. + cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003; 31: 702-707.
11. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph-negative cells in some CML patients in cytogenetic remission to Imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.
12. Gozzetti A, Tozzuoli D, Crupi R, Gentili S, Bocchia M, Raspadori D et al. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate. Eur J Haematol 2003; 71: 313-314.
13. Morel F, Ka C, Le Bris MJ, Herry A, Morice P, Bourquard P et al. Deletion of the 5′ abl region in Philadelphia-positive chronic myeloid leukemia: frequency, origin and prognosis. Leukemia Lymphoma 2003; 44: 1333-1338.